Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs

Molecular Genetics and Metabolism

Volumn 107, Issue 1-2, 2012, Pages 145-152

  Smith, Lachlan J ^a   Martin, John T ^a   O'Donnell, Patricia ^b   Wang, Ping ^b   Elliott, Dawn M ^a,c   Haskins, Mark E ^b   Ponder, Katherine P ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Delaware   (United States)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

Bone; Gene therapy; Gibbus deformity; Intervertebral disk; Lumbar spine; Mucopolysaccharidosis VII

Indexed keywords

BETA GLUCURONIDASE; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIFICATION; CONTROLLED STUDY; DOG; FEMALE; GENE EXPRESSION; GENE THERAPY; LIVER CELL; MALE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; NUCLEUS PULPOSUS; PRIORITY JOURNAL; RANGE OF MOTION; SPINE DISEASE; SURVIVAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANIMALS, NEWBORN; BIOMECHANICAL PHENOMENA; CALCIUM; DOGS; GENETIC THERAPY; GENETIC VECTORS; GLUCURONIDASE; GLYCOSAMINOGLYCANS; LUMBAR VERTEBRAE; MALE; MUCOPOLYSACCHARIDOSIS VII; RETROVIRIDAE; SPINAL DISEASES;

CANIS FAMILIARIS;

EID: 84866146782     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.03.013     Document Type: Article

References (33)

1. Neufeld E.F., Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Baldo G., Wu S., Howe R.A., Ramamoothy M., Knutsen R.H., Fang J., Mecham R.P., Liu Y., Wu X., Atkinson J.P., Ponder K.P. Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol. Genet. Metab. 2011, 104:608-619.
3. Simonaro C.M., Ge Y., Eliyahu E., He X., Jepsen K.J., Schuchman E.H. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:222-227.
4. Wraith J.E. The mucopolysaccharidoses: a clinical review and guide to management. Arch. Dis. Child. 1995, 72:263-267.
5. White K.K., Harmatz P. Orthopedic management of mucopolysaccharide disease. J. Pediatr. Rehabil. Med. 2010, 3:47-56.
6. White K.K. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 2011, 50(Suppl. 5):v26-v33.
7. Pizzutillo P.D., Osterkamp J.A., Scott C.I., Lee M.S. Atlantoaxial instability in mucopolysaccharidosis type VII. J. Pediatr. Orthop. 1989, 9:76-78.
8. Beaudet A.L., DiFerrante N.M., Ferry G.D., Nichols B.L., Mullins C.E. Variation in the phenotypic expression of beta-glucuronidase deficiency. J. Pediatr. 1975, 86:388-394.
9. Sly W.S., Quinton B.A., McAlister W.H., Rimoin D.L. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J. Pediatr. 1973, 82:249-257.
10. Vogler C., Levy B., Kyle J.W., Sly W.S., Williamson J., Whyte M.P. Mucopolysaccharidosis VII: postmortem biochemical and pathological findings in a young adult with beta-glucuronidase deficiency. Mod. Pathol. 1994, 7:132-137.
11. Dickerman R.D., Colle K.O., Bruno C.A., Schneider S.J. Craniovertebral instability with spinal cord compression in a 17-month-old boy with Sly syndrome (mucopolysaccharidosis type VII): a surgical dilemma. Spine 2004, 29:E92-E94.
12. de Kremer R.D., Givogri I., Argarana C.E., Hliba E., Conci R., Boldini C.D., Capra A.P. Mucopolysaccharidosis type VII (beta-glucuronidase deficiency): a chronic variant with an oligosymptomatic severe skeletal dysplasia. Am. J. Med. Genet. 1992, 44:145-152.
13. Arn P., Wraith J.E., Underhill L. Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry. J. Pediatr. 2009, 154:859-864.
14. Haskins M., Casal M., Ellinwood N.M., Melniczek J., Mazrier H., Giger U. Animal models for mucopolysaccharidoses and their clinical relevance. Acta Paediatr. Suppl. 2002, 91:88-97.
15. Haskins M.E., Desnick R.J., DiFerrante N., Jezyk P.F., Patterson D.F. Beta-glucuronidase deficiency in a dog: a model of human mucopolysaccharidosis VII. Pediatr. Res. 1984, 18:980-984.
16. Silverstein Dombrowski D.C., Carmichael K.P., Wang P., O'Malley T.M., Haskins M.E., Giger U. Mucopolysaccharidosis type VII in a German Shepherd Dog. J. Am. Vet. Med. Assoc. 2004, 224:553-557.
17. Ray J., Scarpino V., Laing C., Haskins M.E. Biochemical basis of the beta-glucuronidase gene defect causing canine mucopolysaccharidosis VII. J. Hered. 1999, 90:119-123.
18. Smith L.J., Martin J.T., Szczesny S.E., Ponder K.P., Haskins M.E., Elliott D.M. Altered lumbar spine structure, biochemistry, and biomechanical properties in a canine model of mucopolysaccharidosis type VII. J. Orthop. Res. 2010, 28:616-622.
19. Weisstein J.S., Delgado E., Steinbach L.S., Hart K., Packman S. Musculoskeletal manifestations of hurler syndrome - long-term follow-up after bone marrow transplantation. J. Pediatr. Orthop. 2004, 24:97-101.
20. Horovitz D.D., Magalhães Tde S., Pena e Costa A., Carelli L.E., Souza e Silva D., de Linhares e Riello A.P., Llerena J.C. Spinal cord compression in young children with type VI mucopolysaccharidosis. Mol. Genet. Metab. 2011, 104:295-300.
21. Ponder K.P., Melniczek J.R., Xu L., Weil M.A., O'Malley T.M., O'Donnell P.A., Knox V.W., Aguirre G.D., Mazrier H., Ellinwood N.M., Sleeper M., Maguire A.M., Volk S.W., Mango R.L., Zweigle J., Wolfe J.H., Haskins M.E. Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13102-13107.
22. Mango R.L., Xu L., Sands M.S., Vogler C., Seiler G., Schwarz T., Haskins M.E., Ponder K.P. Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol. Genet. Metab. 2004, 82:4-19.
23. Herati R.S., Knox V.W., O'Donnell P., D'Angelo M., Haskins M.E., Ponder K.P. Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Mol. Genet. Metab. 2008, 95:142-151.
24. Xu L., Haskins M.E., Melniczek J.R., Gao C., Weil M.A., O'Malley T.M., O'Donnell P.A., Mazrier H., Ellinwood N.M., Zweigle J., Wolfe J.H., Ponder K.P. Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs. Mol. Ther. 2002, 5:141-153.
25. Metcalf J.A., Linders B., Wu S., Bigg P., O'Donnell P., Sleeper M.M., Whyte M.P., Haskins M., Ponder K.P. Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression. Mol. Genet. Metab. 2010, 99:396-407.
26. Farndale R.W., Buttle D.J., Barrett A.J. Improved quantitation and discrimination of sulfated glycosaminoglycans by use of dimethylmethylene blue. Biochim. Biophys. Acta 1986, 883:173-177.
27. Sarkar B.C.R., Chauhan U.P.S. A new method for determining micro quantities of calcium in biological materials. Anal. Biochem. 1967, 20:155-166.
28. Ponder K.P., Wang B., Wang P., Ma X., Herati R., Cullen K., O'Donnell P., Ellinwood N.M., Traas A., Primeau T.M., Haskins M.E. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. Mol. Ther. 2006, 14:5-13.
29. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 2001, 344:182-188.
30. Muenzer J., Gucsavas-Calikoglu M., McCandless S.E., Schuetz T.J., Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol. Genet. Metab. 2007, 90:329-337.
31. Wang B., O'Malley T.M., Xu L., Vite C., Wang P., O'Donnell P.A., Ellinwood N.M., Haskins M.E., Ponder K.P. Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol. Genet. Metab. 2006, 87:8-21.
32. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., Pavloff N., Sly W.S. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14777-14782.
33. Rasalkar D.D., Chu W.C., Hui J., Chu C.M., Paunipagar B.K., Li C.K. Pictorial review of mucopolysaccharidosis with emphasis on MRI features of brain and spine. Br. J. Radiol. 2011, 84:469-477.